Related references
Note: Only part of the references are listed.Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
Mikhail A. Nikiforov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
ER stress triggers apoptosis by activating BH3-only protein Bim
Hamsa Puthalakath et al.
CELL (2007)
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
Patricia Perez-Galan et al.
BLOOD (2007)
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines
Sandra J. Strauss et al.
CANCER RESEARCH (2007)
Apoptosis induced by proteasome inhibition in cancer cells:: predominant role of the p53/PUMA pathway
C. G. Concannon et al.
ONCOGENE (2007)
Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells
D. Iglesias-Serret et al.
LEUKEMIA (2007)
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
M. Kraus et al.
LEUKEMIA (2007)
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
Cinta Mestre-Escorihuela et al.
BLOOD (2007)
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer
Yue Y. Shi et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib
Reshma Shringarpure et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
J Codony-Servat et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
E David et al.
BLOOD (2005)
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFβ signalling pathways
EG Rizzatti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors
HB Zhu et al.
ONCOGENE (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Differential regulation of noxa in normal Melanocytes and melanoma cells by proteasome inhibition:: Therapeutic implications
Y Fernández et al.
CANCER RESEARCH (2005)
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue
L Chen et al.
CANCER RESEARCH (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
C Nakanishi et al.
NATURE REVIEWS CANCER (2005)
Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells
CJ Weng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Genome-wide array-based CGH for mantle cell lymphoma:: identification of homozygous deletions of the proapoptotic gene BIM
H Tagawa et al.
ONCOGENE (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
D Chauhan et al.
BLOOD (2004)
Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1
RT Snowden et al.
LEUKEMIA (2003)
Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis
LV Pham et al.
JOURNAL OF IMMUNOLOGY (2003)
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
J Orchard et al.
BLOOD (2003)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Share Paper
